Polyrizon’s (NASDAQ:PLRZ – Get Free Report) lock-up period is set to end on Monday, April 28th. Polyrizon had issued 958,903 shares in its IPO on October 29th. The total size of the offering was $4,199,995 based on an initial share price of $4.38. After the expiration of Polyrizon’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
Polyrizon Stock Up 5.8 %
Shares of PLRZ stock opened at $0.35 on Friday. Polyrizon has a 1-year low of $0.28 and a 1-year high of $4.80. The stock’s 50-day moving average is $0.58.
Institutional Trading of Polyrizon
A hedge fund recently bought a new stake in Polyrizon stock. Citadel Advisors LLC purchased a new position in shares of Polyrizon Ltd. (NASDAQ:PLRZ – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 38,337 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned 0.91% of Polyrizon as of its most recent SEC filing.
Polyrizon Company Profile
Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.
Further Reading
- Five stocks we like better than Polyrizon
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 2 Strong Utilities Plays With Booming Earnings and Room to Grow
- CD Calculator: Certificate of Deposit Calculator
- Why Smart Investors Don’t Panic in Election Season
- What is Insider Trading? What You Can Learn from Insider Trading
- Now Is the Time to Buy ServiceNow—The Rebound Is Real
Receive News & Ratings for Polyrizon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polyrizon and related companies with MarketBeat.com's FREE daily email newsletter.
